China Diagnostic Reagent Industry Report, 2013-2016
-
July 2014
- Hard Copy
- USD
$2,550
-
- Pages:140
- Single User License
(PDF Unprintable)
- USD
$2,400
-
- Code:
ZLC-006
- Enterprise-wide License
(PDF Printable & Editable)
- USD
$3,700
-
- Hard Copy + Single User License
- USD
$2,750
-
With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic reagent industry has been developing quickly, especially in vitro diagnostic reagents occupy over 90%. In 2013, Chinese in vitro diagnostics market size reached RMB22.98 billion, of which RMB16.61 billion came from in vitro diagnostic reagents.
Chinese in vitro diagnostic reagent market consists of biochemical diagnostic reagents, immunodiagnostic reagents and molecular diagnostic reagents. Among them, the immune reagents and biochemical reagents account for a relatively higher combined proportion, such as around 65% in 2013.
Currently, about 40%-50% share of the Chinese in vitro diagnostics market has been dominated by foreign companies represented by Roche, Siemens, Abbott and Johnson & Johnson. Although there are 300-400 local enterprises in China in vitro diagnostics industry, the top ten Chinese companies which rank by production scale only seize 30% market share, reflecting a low industry concentration degree.
Mindray Medical, KHB, Fosun Pharmaceutical, Maker Biotechnology and Da An Gene act as giants in China in vitro diagnostics industry. Especially, Mindray Medical and KHB achieved the respective in vitro diagnostics revenue of RMB2.0458 billion and RMB1.0572 billion in 2013, accounting for 13.5% of the total jointly.
In 2014, a number of local Chinese diagnostic reagent companies (including BSBE, Maker Biotechnology, Health BioMed, Wondfo, Thalys) intend to step in the capital market through IPO because they are optimistic about the prospects of the diagnostic reagent industry; the raised funds will be used in the expansion of the existing projects or the construction of new projects. SHINVA, Humanwell Healthcare and Zhongyuan Union Stem Cell Bioengineering have entered the diagnostic reagent industry through acquisitions.
The report covers the following:
Status quo of China diagnostic reagent industry, including overview, market structure, import, export, competition pattern and so on;
Development environments and trends of China diagnostic reagent industry, embracing macroeconomy, medical situation, and relevant policies;
Operation and diagnostic reagent business of 17 major companies in China diagnostic reagent industry.
1 Overview of Diagnostic Reagent Industry
1.1 Definition
1.2 Classification
1.3 Industry Chain
2 Status Quo of China Diagnostic Reagent Industry
2.1 Overview
2.2 Market Structure
2.3 Import and Export
2.3.1 Import
2.3.2 Export
2.4 Competition Pattern
2.5 Market Segments
2.5.1 Biochemical Diagnostic Reagents
2.5.2 Immunodiagnostic Reagents
2.5.3 Molecular Diagnostic Reagents
2.5.4 Comprehensive In Vitro Diagnostic Reagents
3 Development Environments and Trends of China Diagnostic Reagent Industry
3.1 Positive Factors
3.1.1 Macroeconomy
3.1.2 Medical Care
3.1.3 Policies
3.2 Trends
3.2.1 Biochemical Immunodiagnostics is still the Mainstream
3.2.2 High Industrial Concentration Degree
3.2.3 Integrated Enterprises will See Better Development
4 Major Enterprises
4.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R & D and Investment
4.1.6 Supply and Marketing
4.1.7 In Vitro Diagnostics Business
4.1.8 Anticipation and Outlook
4.2 Beijing Strong Biotechnologies, Inc (BSBE)
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R & D and Investment
4.2.6 Production and Marketing
4.2.7 Supply and Marketing
4.2.8 Anticipation and Outlook
4.3 Da An Gene
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R & D and Investment
4.3.6 Diagnostic Reagent Business
4.3.7 Supply and Marketing
4.3.8 Anticipation and Outlook
4.4 Fosun Pharmaceutical
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R & D and Investment
4.4.6 Diagnostic Reagent Business
4.4.7 Anticipation and Outlook
4.5 Beijing Leadman Biochemistry Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R & D and Investment
4.5.6 Clients
4.5.7 Anticipation and Outlook
4.6 Livzon Pharmaceutical Group Inc.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 R & D
4.6.6 Diagnostic Reagent Business
4.6.7 Anticipation and Outlook
4.7 Mindray Medical
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R & D and Investment
4.7.6 Diagnostic Reagent Business
4.7.7 Anticipation and Outlook
4.8 Biosino Bio-Technology & Science Inc.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 Gross Margin
4.8.5 Anticipation and Outlook
4.9 Maker Biotechnology
4.9.1 Profile
4.9.2 Operation
4.9.3 Revenue Structure
4.9.4 Gross Margin
4.9.5 R & D and Investment
4.9.6 Supply and Marketing
4.9.7 Production and Marketing
4.9.8 Anticipation and Outlook
4.10 Sinocare
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Gross Margin
4.10.5 Anticipation and Outlook
4.11 Beijing Kinghawk Pharmaceutical Co., Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Revenue Structure
4.11.4 Gross Margin
4.11.5 Anticipation and Outlook
4.12 Bohui Innovation
4.12.1 Profile
4.12.2 Operation
4.12.3 Revenue Structure
4.12.4 Gross Margin
4.12.5 R & D and Investment
4.12.6 Anticipation and Outlook
4.13 Health BioMed
4.13.1 Profile
4.13.2 Operation
4.13.3 Revenue Structure
4.13.4 Gross Margin
4.13.5 Supply and Marketing
4.13.6 R & D and Investment
4.13.7 Anticipation and Outlook
4.14 Wondfo
4.14.1 Profile
4.14.2 Operation
4.14.3 Revenue Structure
4.14.4 Gross Margin
4.14.5 Supply and Marketing
4.14.6 R & D and Investment
4.14.7 Anticipation and Outlook
4.15 Thalys
4.15.1 Profile
4.15.2 Operation
4.15.3 Revenue Structure
4.15.4 Gross Margin
4.15.5 Production and Marketing
4.15.6 Supply and Marketing
4.15.7 R & D and Investment
4.15.8 Anticipation and Outlook
4.16 SHINVA
4.16.1 Profile
4.16.2 Operation
4.16.3 Gross Margin
4.16.4 Diagnostic Reagent Business
4.17 Humanwell Healthcare
4.17.1 Profile
4.17.2 Operation
4.17.3 Diagnostic Reagent Business
5 Summary and Forecast
5.1 Anticipation and Outlook of China Diagnostic Reagent Industry
5.2 Operation Comparison between Major Companies
5.2.1 Revenue
5.2.2 Net Income
5.2.3 Gross Margin
5.2.4 In Vitro Diagnostics Business
Classification of In Vitro Diagnostic Reagents (by Detection Principle)
In Vitro Diagnostic Reagent Categories and Products (by National Policies)
Diagnostic Reagent Industry Chain
China’s In Vitro Diagnostics Market Size, 2009-2013
China’s In Vitro Diagnostic Reagent Market Structure, 2013
China’s Diagnostic Reagent Import Volume, 2008-2013
China’s Diagnostic Reagent Import Value, 2008-2013
China’s Diagnostic Reagent Import Sources and Value, 2012-2013
China’s Diagnostic Reagent Export Volume, 2008-2013
China’s Diagnostic Reagent Export Value, 2008-2013
Top 10 Destinations of Chinese Diagnostic Reagents by Export Volume and Value, 2012-2013
Diagnostic Instrument Comparison between Domestic and Foreign Enterprises
Competition Pattern of China Diagnostic Reagent Industry
In Vitro Diagnostics Revenue and Market Share of Major Diagnostic Reagent Companies in China, 2013
China’s GDP and YoY Growth Rate, 2004-2013
China’s Total Population and YoY Growth Rate, 2006-2013
Population of 65-year-old People (or Older) and % of Total Population in China, 2004-2013
China's Health Expenditure and % of GDP, 1980-2013
China's Per Capita Health Expenditure and YoY Growth Rate, 2006-2012
Number of Medical Institutions In China, 2012-2013
Workload of Health Institutions in China, 2012-2013
Main Policies of China Diagnostic Reagent Industry, 2010-2013
Development Process of Roche Diagnostics
Integrated Development Strategies of Global Leading Diagnostic Reagent Companies
KHB’s Revenue and Net Income, 2009-2013
KHB’s Revenue (by Product), 2009-2013
KHB’s Revenue Structure (by Product), 2009-2013
KHB’s Revenue (by Region), 2009-2013
KHB’s Revenue Structure (by Region), 2009-2013
KHB’s Gross Margin, 2009-2013
KHB’s Gross Margin (by Product), 2009-2013
KHB’s Gross Margin (by Region), 2010-2013
KHB’s R & D Costs and % of Total Revenue, 2011-2013
Key National Projects Involved with KHB
KHB’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Comparison between KHB’s Top 5 Clinets, 2012-2013
Comparison between KHB’s Top 5 Suppliers, 2012-2013
KHB’s Medical Instrument Categories and Products, 2013
KHB’s Revenue and Net Income, 2012-2016E
BSBE’s Revenue and Net Income, 2011-2013
BSBE’s Revenue and Structure (by Product), 2011-2013
BSBE’s Gross Margin, 2011-2013
Gross Margin of BSBE’s Independent Products, 2011-2013
Gross Margin of BSBE’s Agent Products, 2011-2013
BSBE’s R & D Costs and % of Total Revenue, 2011-2013
BSBE’s Investment Projects and Value
BSBE’s Capacity, Output and Sales Volume, 2011-2013
BSBE’s Top 10 Products by Sales, 2013
BSBE’s Top 5 Raw Material Suppliers, 2011-2013
BSBE’s Top 5 Distributors, 2011-2013
BSBE’s Revenue and Net Income, 2011-2016E
Revenue and Net Income of Da An Gene, 2009-2013
Revenue of Da An Gene (by Product) , 2009-2013
Revenue Structure of Da An Gene (by Product) , 2009-2013
Revenue of Da An Gene (by Region), 2009-2013
Revenue Structure of Da An Gene (by Product) , 2009-2013
Gross Margin of Da An Gene, 2009-2013
Gross Margin of Da An Gene (by Product), 2009-2013
R & D Costs and % of Total Revenue of Da An Gene, 2011-2013
Reagent Revenue and YoY Growth of Da An Gene, 2009-2013
Instrument Revenue and YoY Growth Rate of Da An Gene, 2009-2013
Principal Assets and Business of Da An Gene
Medical Resources of Sun Yat-sen University
Top 5 Clients of Da An Gene, 2013
Top 5 Clients of Da An Gene, 2012
Top 5 Suppliers of Da An Gene, 2013
Top 5 Suppliers of Da An Gene, 2012
Revenue and Net Income of Da An Gene, 2012-2016E
Revenue and Net Income of Fosun Pharmaceutical, 2009-2013
Revenue of Fosun Pharmaceutical (by Business), 2009-2013
Revenue Structure of Fosun Pharmaceutical (by Business), 2009-2013
Revenue of Fosun Pharmaceutical (by Region), 2009-2013
Revenue Structure of Fosun Pharmaceutical (by Region), 2009-2013
Gross Margin of Fosun Pharmaceutical, 2009-2013
Gross Margin of Fosun Pharmaceutical (by Business), 2009-2013
R & D Costs and % of Total Revenue of Fosun Pharmaceutical, 2010-2013
Medical Diagnosis and Medical Equipment Revenue as well as % of Total Revenue of Fosun Pharmaceutical, 2009-2013
Revenue and Net Income of Fosun Pharmaceutical, 2012-2016E
Leadman's Revenue and Net Income, 2009-2013
Leadman's Revenue (by Product), 2009-2013
Leadman's Revenue Structure (by Product), 2009-2013
Leadman's Gross Margin, 2009-2013
Leadman's Gross Margin (by Product), 2009-2013
Leadman's R & D Costs and% of Total Revenue, 2011-2013
Leadman's Top 5 Clients, 2013
Leadman's Top 5 Clients, 2012
Leadman's Revenue and Net Income, 2012-2016E
Livzon’s Revenue and Net Income, 2009-2013
Livzon’s Revenue (by Product), 2009-2013
Livzon’s Revenue Structure (by Product), 2009-2013
Livzon’s Revenue (by Region), 2009-2013
Livzon’s Revenue Structure (by Region), 2009-2013
Livzon’s Gross Margin, 2009-2013
Livzon’s Gross Margin (by Product), 2009-2013
Livzon’s Main Diagnostic Reagent Products
Revenue and YoY Growth Rate of Livzon’s Diagnostic Reagents and Equipment, 2009-2013
Livzon’s Revenue and Net Income, 2012-2016E
Revenue and Net Income of Mindray Medical, 2009-2013
Revenue of Mindray Medical (by Product), 2009-2013
Revenue Structure of Mindray Medical (by Product), 2009-2013
Gross Margin of Mindray Medical, 2009-2013
R & D Costs and % of Total Revenue of Mindray Medical, 2009-2013
In Vitro Diagnostic Product Revenue and YoY Growth Rate of Mindray Medical, 2009-2013
Revenue and Net Income of Mindray Medical, 2012-2016E
Biosino’s Revenue and Net Income, 2009-2013
Biosino’s Revenue (by Product), 2009-2013
Biosino’s Revenue Structure (by Product), 2009-2013
Biosino’s Gross Margin, 2009-2013
Biosino’s Revenue and Net Income, 2012-2016E
Product Structure of Maker Biotechnology
Revenue and Net Income of Maker Biotechnology, 2011-2013
Sales and Structure of Independent Products of Maker Biotechnology, 2011-2013
Agent Brand Sales and Structure of Maker Biotechnology, 2011-2013
Sales and Structure of Maker Biotechnology (by Client), 2011-2013
Comparison between Direct sales and Distribution Revenue of Maker Biotechnology (by Region), 2011-2013
Gross Margin of Maker Biotechnology, 2011-2013
R & D Costs and % of Total Revenue of Maker Biotechnology, 2011-2013
Investment Projects and Value of Maker Biotechnology
Top 10 Suppliers of Maker Biotechnology, 2012-2013
Dealer Distribution of Maker Biotechnology, 2011-2013
Top 5 Clients of Maker Biotechnology, 2011-2013
Capacity, Output and Sales Volume of Maker Biotechnology, 2011-2013
Comparison between Independent Diagnostic Products and Agent Diagnostic Products of Maker Biotechnology
Revenue and Net Income of Maker Biotechnology, 2012-2016E
Sinocare’s Revenue and Net Income, 2009-2013
Sinocare’s Revenue Structure (by Product), 2009-2013
Sinocare’s Gross Margin, 2009-2013
Sinocare’s Gross Margin (by Product), 2009-2013
Sinocare’s Revenue and Net Income, 2012-2016E
Revenue and Net Income of Kinghawk Pharmaceutical, 2009-2013
Revenue of Kinghawk Pharmaceutical (by Product), 2010-2012
Revenue Structure of Kinghawk Pharmaceutical (by Product), 2010-2012
Gross Margin of Kinghawk Pharmaceutical, 2009-2013
Gross Margin of Kinghawk Pharmaceutical (by Product), 2010-2012
Revenue and Net Income of Kinghawk Pharmaceutical, 2012-2016E
Revenue and Net Income of Bohui Innovation, 2009-2013
Revenue of Bohui Innovation (by Product), 2009-2013
Revenue Structure of Bohui Innovation (by Product), 2009-2013
Gross Margin of Bohui Innovation, 2009-2013
Gross Margin of Bohui Innovation (by Product), 2009-2013
R & D Costs and % of Total Revenue of Bohui Innovation, 2010-2013
Revenue and Net Income of Bohui Innovation, 2012-2016E
Revenue and Net Income of Health BioMed, 2011-2013
Revenue and Structure of Health BioMed (by Product), 2011-2013
Revenue and Structure of Health BioMed (by Region), 2011-2013
Revenue and Structure of Health BioMed (by Client), 2011-2013
Gross Margin of Health BioMed, 2011-2013
Gross Margin of Health BioMed (by Product), 2011-2013
Top 5 Suppliers of Health BioMed, 2011-2013
Top 5 Clients of Health BioMed, 2011-2013
R & D Costs and % of Total Revenue of Health BioMed, 2011-2013
In Vitro Diagnostic Items, Product Categories and Operation Modes of Health BioMed
Investment Projects and Value of Health BioMed
Revenue and Net Income of Health BioMed, 2011-2016E
Application and Detection Methods of Wondfo's Products
Wondfo’s Revenue and Net Income, 2011-2013
Wondfo’s Revenue (by Product), 2011-2013
Wondfo’s Revenue Structure (by Product), 2011-2013
Wondfo’s Revenue (by Region), 2011-2013
Wondfo’s Gross Margin, 2011-2013
Wondfo’s Gross Margin (by Product), 2011-2013
Wondfo’s Top 5 Suppliers, 2011-2013
Wondfo’s Top 5 Clients, 2011-2013
Wondfo’s R & D Costs and % of Total Revenue, 2011-2013
Wondfo’s Investment Projects and Purposes of Raised Funds
Wondfo’s Revenue and Net Income, 2011-2016E
Revenue and Net Income of Thalys, 2011-2013
Revenue and Structure of Thalys (by Business), 2011-2013
Revenue and Structure of Thalys (by Region), 2011-2013
Gross Margin of Thalys, 2011-2013
Gross Margin of Thalys (by Business), 2011-2013
Capacity, Output, Sales Volume, Capacity Utilization and Sales/Output Ratio of Thalys’ Independent Products, 2011-2013
Top 5 Clients of Thalys, 2011-2013
Top 5 Suppliers of Thalys, 2011-2013
Sales and R & D COSTS of Thalys’ Independent Products, 2011-2013
Investment Projects and Raised Funds of Thalys
Revenue and Net Income of Thalys, 2011-2016E
SHINVA’s Revenue and Net Income, 2009-2013
SHINVA’s Gross Margin, 2009-2013
Revenue and Net Income of Humanwell Healthcare, 2009-2013
Chinese In Vitro Diagnostics Market Size, 2012-2016E
Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Net Income Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Net Profit Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
Gross Margin Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
In Vitro Diagnostics Revenue Comparison between Major Companies in China Diagnostic Reagent Industry, 2009-2013
China Diagnostic Reagent Industry Report, 2013-2016
With the accelerated aging of the Chinese population, the increase of personal health expenditure as well as the improved medical care facilities and government health care system, China diagnostic re...
China Hemodialysis Equipment Import and Export Report, 2013-2016
Hemodialysis equipment is the most widely used treatment apparatus in blood purification, primarily targeting patients with acute or chronic renal failure.The Chinese hemodialysis equipment market sho...
Global and China Hemodialysis Industry Report, 2013-2016
Hemodialysis, also known as artificial kidney, is a type of blood purification technology, primarily applicable to the treatment of patients with rental failure.
In 2013, the global number of patient...
China Portable Medical Equipment Industry Report, 2013-2016
With the synergy of favorable policies, improvement in living standards and healthcare awareness raising, China’s portable medical device industry has shown rapid development in recent years, with mar...
China Medical Informatization Industry Report,2013-2016
Under the impetus of multiple favorable policies and market demand, China's medical informatization industry has entered a rapid development stage in recent years. As of the first half of 2013, manage...
China Aged Care Industry Report, 2013-2016
Currently, China has entered the accelerated aging period. China’s population aged 65 and above reached 131.61 million in 2013, accounting for 9.7% of total population; and the proportion will rise to...
China Pharmaceutical Equipment Industry Report, 2013-2016
After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total pro...
China Dental Industry Report, 2013-2016
The dental industry refers to medical industrial chain on the basis of oral medical consumption, consisting mainly of dental appliances (equipments and consumables), dental medical services, etc. with...
China Medical Monitor Industry Report, 2013-2015
In 2007-2011, the Chinese medical monitor market size rose from RMB1.16 billion to RMB3.08 billion at a CAGR of 27.8%. In 2012, the figure reached RMB3.86 billion, a year-on-year increase of 25.3%, of...
China Interventional Cardiovascular Device Industry Report, 2013-2015
With the accelerated aging, the prevalence of cardiovascular diseases in China increased year by year. According to statistics of National Health and Family Planning Commission of the People’s Republi...
China Diagnostic Reagent Industry Report, 2013-2015
Driven by huge population base, intensified aging and many favorable policies, China diagnostic reagent industry has been developing rapidly. In 2008-2012, the diagnostic reagent market size presented...
China Orthopedic Instrument Industry Report, 2013-2015
Benefiting from aging of population, consumption upgrade and policy support, China's orthopedic instrument industry has seen rapid development over the years, with total market size rising from 3.28 b...
China Ophthalmic Hospital Industry Report, 2012-2015
With the growing types of eye diseases and non-basic medical needs, China’s ophthalmic hospital industry has seen rapid development. In 2011, the number of ophthalmic hospitals in China reached 288, w...
China Chinese Patent Medicine Industry Report, 2012-2015
In recent years, China’s Chinese patent medicine industry has been running in good condition, with the revenue increasing from RMB 142 billion in 2008 to RMB 360 billion in 2012 at a CAGR of 26.2%. Ov...
China Aged Care Industry Report, 2012-2015
At present, China’s population aging has entered the accelerated phase. In 2012, 194 million people were at or above 60 years old, accounting for 14.3% of the total population. In 2013, the aged popul...
China Hospital Industry Development and Investment Report, 2012-2015
China hospital industry has maintained stable growth in recent years, thanks to the market demand stimulus and stable influx of national investment. As of late 2011, China had a total of 21,979 hospit...
China Contract Research Organization (CRO) Industry Report, 2012-2013
Compared to Europe and America, China developed pharmaceutical CRO industry 40 years later, with domestic industrial players amounting to over 500, most of which are SMEs. In general, Chinese CRO mark...
Global and China Hemodialysis Industry Report, 2012-2013
Hemodialysis is also regarded as artificial kidney, a kind of blood purification targeting mainly at the treatment of renal failure patients. In 2011, the global dialysis population hit 2.158 million,...